New vaccine introduction
No content found

Join us for a webinar: Findings from a healthcare worker evaluation of the COVID-19 vaccine label

Description: PATH’s Living Labs Initiative used human-centered design methods to gather feedback on proposed labels f

Mini-cPIE, aka COVID-19 Vaccination Intra-action Review (IAR)

Are there facilitators and particpant guide for training on Mini PIE for covid19 ?

COVID-19 Vaccination webinar #9: Vaccination strategies for COVID-19 vaccination

You can already register to the next session of the Webinar series for National/subnational Focal Points on COVID-19 Vaccination: Planning and Implementat

Considerations for optimizing deployment of AstraZeneca/AXD1222 and SII/Covishield vaccines in a time -limited constrained supply situation

UPDATE (5 MAY) This working copy of the document Considerations for optimizing deployment of ChAdOx1-S [recombinant] vaccines in a time-limited constrained supply situation (AstraZe

COVID-19 Vaccination webinar #7: Generating acceptance and demand for COVID-19 vaccines/ supporting community led activities and reaching key influencers

The Access to COVID-19 Tools (ACT) Accelerator’s Country Readiness and Delivery (CRD) workstream, Project ECHO, Boost, TechNet-21, and the COVID-19 Vaccine Equity Project invite you to join a ser

COVID-19 Vaccination webinar #6: Understanding COVID-19 vaccines - safety and efficacy

The Access to COVID-19 Tools (ACT) Accelerator’s Country Readiness and Delivery (CRD) workstream, Project ECHO, Boost, TechNet-21, and the COVID-19 Vaccine Equity Project invite you to join a ser

COVIDE-19 Vaccination webinar #5: Regulatory and Procurement Aspects for COVID-19 Vaccines

The Access to COVID-19 Tools (ACT) Accelerator’s Country Readiness and Delivery (CRD) workstream, Project ECHO, Boost, TechNet-21, and the COVID-19 Vaccine Equity Project invite you to join a ser

COVID-19 Vaccination webinar #4: Infection prevention and control for COVID-19 vaccine introduction

The Access to COVID-19 Tools (ACT) Accelerator’s Country Readiness and Delivery (CRD) workstream, Project ECHO, Boost, TechNet-21, and the COVID-19 Vaccine Equity Project invite you to join a ser

COVID-19 Vaccination webinar #3: Indemnification & Liability

The Access to COVID-19 Tools (ACT) Accelerator’s Country Readiness and Delivery (CRD) workstream, Project ECHO, Boost, TechNet-21, and the COVID-19 Vaccine Equity Project invite you to join a ser

Covid-19 vaccine introduction new Telegram channels

Dear colleagues,  TechNet-21 is pleased to invite you to two new Telegram channels supporting regions, countries, and partners in preparing for COVID-19 vaccine introduction. In these

Estas recomendaciones provisionales se refieren a la vacuna contra la COVID-19 fabricada por Novavax y el Serum Institute of India a partir de nanopartículas de proteínas recombinantes formuladas con el adyuvante Matrix M por Novavax...

Ces recommandations provisoires concernent le vaccin anti-COVID-19 mis au point par Novavax et Serum Institute of India qui utilise la plateforme Novavax de nanoparticules de protéines recombinantes associées à l’adjuvant Matrix M...

Fact sheet for HPV vaccine introduction in Tanzania

This video was developed by the Immunization Academy for use both in and outside of Tanzania.

Banner for HPV vaccine introduction in Senegal

Flyer for HPV vaccine introduction in Senegal

HPV vaccine introduction posters from Senegal

HPV vaccine introduction communication plan for Senegal

Tire cover communication material for HPV vaccination program in Tanzania

Leaflet for HPV vaccination program in Tanzania

Banner used during HPV vaccination program in Tanzania

Poster for HPV vaccine introduction

Advocacy, communication and social mobilization communication plan for HPV vaccine introduction in Tanzania

Tanzania rolling advocacy, communication, and social mobilization strategy. (DRAFT)

Communication materials developed for cohort 1 and cohort 2. Also available in Shona and Ndebele.

Communication materials developed for cohort 1 and cohort 2. Also available in Shona and Ndebele.

Communication materials developed for cohort 1 and cohort 2. Shona and Ndebele versions also available.

Communication plan developed prior to cohort 2 (2019 campaign)

Tanzania Routine Immunization health facility register including HPV vaccine

Daily tally sheet used for multi-age cohort 1 (2018 campaign)

Tanzania's Roll Out Plan identifies responsible EPI person and technical partner, deliverables, and timeline for main HPV vaccine introduction activities.

HPV vaccine and IPV introduction training were combined as they were being introduced simultaneously.

Tools used for microplanning for HPV vaccine introduction

HPV vaccine introduction training and microplanning slides. HPV vaccine and IPV introduction training were combined as they were being introduced simultaneously. The slide decks included are those specific to HPV vaccine or which covered both...

Field guide for vaccinators and teachers for HPV vaccine introduction in Zimbabwe

Training agenda used in Kwekwe district as part of HPV vaccine introduction.

Questionnaires used for readiness assessment prior to national HPV vaccine introduction in Zimbabwe.

Communication Material for HPV vaccination program in Senegal

The 42nd Global Advisory Committee on Vaccine Safety (GACVS) virtual meeting in May 2020 addressed pharmacovigilance preparedness for the launch of the future COVID-19 vaccines. One of their recommendations was that infrastructure and capacity for...

To support national immunization programme managers to optimize the introduction and implementation of influenza immunization programmes in countries, WHO has developed the Influenza Post Introduction Evaluation tool (IPIE). This tool is designed to...

This study provides the most updated understanding of current and future global trends and drivers of supply and demand for HPV vaccine. It also identifies actions to help address the current and expected constraints and serves as an important...

The WHO vaccine market intelligence database compiles vaccine purchase (product, price and procurement) data as reported by countries via the WHO/UNICEF Joint Reporting Form (JRF) over the period of 2013–2018. While country names are not...

The human papillomavirus (HPV) vaccination school-based programme for girls aged 12–13 years began in Ireland in 2010. Initially, the proportion of students who completed the vaccination course was above 80%. However, the proportion of girls who...

WHO website for NUVI - Resources for monitoring and surveillance.

This essential resource document reviews the principles and issues to be considered when making decisions about planning and implementing the introduction of a vaccine into a national immunization programme. Importantly, the document highlights...

With the previous edition of Immunization in Practice (IIP) having been translated and used throughout the world, we realized the tremendous responsibility we had when we embarked on this new version. This new edition has seven modules instead of...

This document brings together a range of resources to provide an overview of the global policies, potential interventions and strategies related to the integration of immunization services. It also provides guidance and country examples on the...

This Facts Sheet informs of the availability of Measles vaccine and combined Measles-Rubella (MR) vaccine in both a 10-dose vial and a 5-dose vial presentations through (or via) UNICEF procurement.

Zimbabwe Provincial Macroplanning Tool for HPV

Zimbabwe Microplanning Tool (District level) for HPV

Vaccination with Human Papillomavirus (HPV) vaccine is recommended for 11–12 years-old, but uptake is suboptimal. Current messaging focuses on HPV infection transmission and prevention. Parents and providers are often uncomfortable discussing...

Shanchol™, a WHO-prequalified oral cholera vaccine (OCV), has been used to control endemic cholera in Asia, as well as in emergencies and outbreaks elsewhere. The vaccine has not been used by public health systems in cholera-endemic settings of...

Live oral rotavirus (RV) vaccines used worldwide are most effective in reducing diarrheal hospitalizations from RV in high income countries and least effective in low income countries where RV remains a prime cause of death in children. Research has...

To summarize and critically evaluate the evidence on the impact and effectiveness of meningococcal vaccination programs around the world in order to inform decision-making in Latin America and the Caribbean. Methods. A review of the literature was...

Three highly effective vaccines are available to prevent human papillomavirus (HPV) infection, and they have been introduced in many countries around the world. This article describes advances and challenges in introducing HPV vaccines in the...

Conflicting reports have emerged about the effectiveness of the live attenuated influenza vaccine. The live attenuated influenza vaccine appears to protect particularly poorly against currently circulating H1N1 viruses that are derived from the 2009...

Background: Due to competing health priorities and limited resources, many low-income countries, even those with a high disease burden, are not able to introduce pneumococcal conjugate vaccines. Objective: To determine the cost-utility of 10- and...

Infections due to hepatitis B virus (HBV) are a leading cause of death worldwide. WHO estimated that in 2015, 257 million people globally were living with chronic HBV infection and that 887 000 deaths occurred due to HBV, mostly from longterm...

No content found
No content found